At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ALZN Alzamend Neuro, Inc
Trading 01-12 12:53:30 EST
2.34
-0.06
-2.71%
High2.41
Low2.20
Vol28.58K
Open2.41
D1 Closing2.40
Amplitude8.75%
Mkt Cap8.88M
Tradable Cap8.84M
Total Shares3.80M
T/O66.96K
T/O Rate0.76%
Tradable Shares3.78M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Director Milton C. Ault III Reports Sale of Alzamend Neuro Inc. Common Shares
BRIEF-Alzamend Neuro Announces Completion Of Clinical Portion Of Phase Ii Clinical Trial Of Al001 "Lithium In Brain" Study Conducted At Massachusetts General Hospital
Alzamend Neuro Announces Completion of Clinical Portion of Phase Ii Clinical Trial of Al001 "Lithium in Brain" Study Conducted at Massachusetts General Hospital
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. The company has partnership agreement with Massachusetts General Hospital for the Phase II clinical trial of AL001. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.